Esperion Therapeutics Provides Update on the ETC1002 Development Program Following EndofPhase 2 Meeting With FDA

ANN ARBOR MIMarketwired August 17 2015 Esperion Therapeutics Inc. NASDAQ ESPR an emerging pharmaceutical company focused on developing and commercializing firstinclass oral lowdensity lipoprotein cholesterol LDLC lowering therapies for the treatment of p...